New eye drug shows promise for blinding disease

NCT ID NCT06164587

Completed Disease control Sponsor: Inflammasome Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 21, 2026 · Updated 3 times

Summary

This early-stage trial tests an experimental drug called Kamuvudine-8 (K8) for people with geographic atrophy, a form of advanced age-related macular degeneration that causes vision loss. About 30 participants receive eye injections of K8 and are monitored for 26 weeks to check safety and whether the drug can slow vision decline or damage. The goal is to see if K8 is safe and worth testing in larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AGE-RELATED MACULAR DEGENERATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

age-related macular degeneration dry age related macular degeneration Geographic Atrophy macular degeneration

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

Hilton Head Retina Institute

Hilton Head, South Carolina, 29926-2277, United States
Loma Linda University

Loma Linda, California, 92354, United States
Ophthalmology LTD

Sioux Falls, South Dakota, 57108, United States
Oregon Eye Consultants, Cascade Medical Research

Eugene, Oregon, 97401, United States
Southeastern Retina Associates

Hixson, Tennessee, 37343, United States
Southeastern Retina Associates

Bristol, Virginia, 24201, United States
The Maine Eye Center

Portland, Maine, 04101, United States
University of Kentucky Advanced Eye Care

Lexington, Kentucky, 40508, United States
Vistar Eye Center

Roanoke, Virginia, 24019, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.